At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 220 enrolled
Drug / intervention
Baricitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
In Brief
A Phase 3 clinical trial evaluating Baricitinib and Placebo for Juvenile Idiopathic Arthritis. Completed, enrolled 220 participants across 86 sites in 20 countries.
Detailed Summary
The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with JIA from 2 years to less than 18 years old.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsJuvenile Idiopathic Arthritis
CountriesArgentina, Australia, Austria, Belgium, Brazil, China, Czechia, Denmark, France, Germany, India, Israel, Italy, Japan, Mexico, Poland, Russia, Spain, Turkey (Türkiye), United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedDec 2018
Enrollment StartDec 2018
Primary CompletionJan 2022
TodayJul 2026
First PostedDec 12, 2018
Enrollment StartDec 17, 2018
Primary CompletionJan 26, 2022
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 7.6 years ago
Interventions
Baricitinibdrug
Administered orally.
Placebodrug
Administered orally.